The analysis by policy research centre Future Health, using data from the National Ovarian Cancer Audit, examined ovarian ...
Four-in-10 women with ovarian cancer are only diagnosed after an emergency trip to A&E, a damning report has revealed. Survival rates in the UK have been lagging behind the rest of Europe for some ...
Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved ...
A study highlights a gap in cancer prevention, showing men undergo genetic testing less often yet are more likely to carry high-risk cancer variants.
5don MSN
Universal, ready-to-use immunotherapy detects and destroys endometrial cancer in preclinical tests
Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival ...
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and Drug ...
Treating ovarian cancer remains a race against time. In Italy, eight out of ten women receive a late diagnosis, often when the disease is already at an advanced stage. To provide concrete ...
Cancer death rates in the UK have hit a record low, but the picture is more complicated than the headline figure suggests.
Ovarian cancer (OC) is a "silent killer" with an annual incidence of 11.2 per 100,000 and mortality of 7.6 per 100,000. Most cases are diagnosed at ...
Caris AI Insights are proprietary and only available to Caris Life Sciences customers. IRVING, Texas, /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leadin ...
Practice-changing data in endometrial cancer support checkpoint inhibitor–chemotherapy combinations, extending ...
Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS improvements, addressing a high unmet need in platinum-resistant ovarian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results